Inclusion Criteria:

          1. Provision of signed and dated informed consent form

          2. Stated willingness to comply with all study procedures and availability for the
             duration of the study

          3. Male or female, aged 18 years and older

          4. Diagnosed with GBM deemed to be potentially resectable and who are deemed to be good
             candidate for postoperative adjuvant chemo and radiation therapy. This may include
             patients whose tumors are deemed suitable for gross total resection as well as
             patients whose tumors are deemed partially resectable and who undergo partial
             resection followed by adjuvant therapy. [neoadjuvant therapy is rarely if ever
             given]..

          5. Ability to adhere to the bi-weekly injections of DC vaccine regimen

          6. For females of reproductive potential: use of highly effective contraception for at
             least 1 month prior to screening and agreement to use such a method during study
             participation and for an additional 12 weeks following discontinuations of last
             vaccination. Must have a negative serum pregnancy test prior to first treatment.

          7. For males of reproductive potential: use of condoms or other methods to ensure
             effective contraception with partner during study participation and for an additional
             12 weeks following discontinuations of last vaccination.

          8. Presented at Tumor Board for review and consensus of Multidisciplinary group to
             proceed with enrollment.

          9. Adequate kidney, liver, bone marrow function, and immune function, as follows:

               1. Hemoglobin ≥ 8.0 gm/dL

               2. Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3

               3. Platelet count ≥ 100,000 /mm3

               4. Lymphocyte count greater than 500/L

               5. Glomerular filtration rate (GFR) > 60 mL/min/m2 and Creatinine < 1.5mg/dl

             i. For males = (140 - age[years]) x (body weight [kg]) (72) x (serum creatinine
             [mg/dL] ii. For females = 0.85 x male value f. Total bilirubin ≤ 1.5 times upper limit
             of normal (ULN), g. Aspartate transaminase AST (SGOT) and alanine aminotransferase ALT
             (SGPT) ≤ 2.5 times the ULN h. Albumin >2g/dL i. (IgM), surface antibody and antigen,
             Hepatitis B and C antibody. j. Negative HIV status

         10. ECOG performance status ≤ 2.

        Exclusion Criteria:

          1. Locally advanced tumors deemed unresectable and/or recurrent tumors after prior
             vaccination.

          2. Use of non-standard post-operative treatment regimen, as defined by the Stupp
             protocol: postoperative chemoradiation and initiation of TMZ. The use of a TTF device
             with adjuvant TMZ is at the discretion of the investigator.

          3. Female patients who are pregnant, breast feeding, or of childbearing potential without
             a negative pregnancy test prior to baseline. Post-menopausal women must be amenorrheic
             for at least 12 months to be considered of non-childbearing potential.

          4. Patients unwilling or unable to comply with the protocol or provide informed consent.

          5. Any severe or uncontrolled medical condition or other condition that could affect
             participation in this study, including but not limited to: hyper/hypothyroidism,
             systemic autoimmune disorders, untreated viral hepatitis or autoimmune hepatitis.

          6. Concurrent or expected need for therapy with corticosteroids during the vaccination
             phase of the study.

          7. Treatment with another investigational drug or other intervention outside of the
             prespecified standard of care for GBM.

          8. Patients suffering from active HIV disease.